Skip to main content
SpringerLink
Log in

Retinochoroidopathie nach intravitrealer Anti-VEGF-Behandlung

Retinochoroidopathy after intravitreal anti-VEGF treatment

  • Kasuistiken
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

Zusammenfassung

Ein 74-jähriger Patient stellte sich 2 Wochen nach intravitrealer Bevacizumab-Injektion bei choroidaler Neovaskularisation (CNV) aufgrund einer exsudativen altersabhängigen Makuladegeneration wegen persistierender Metamorphopsien am rechten Auge vor. Die Diagnose ergab eine Retinochoroiditis als okuläre Sarkoidosemanifestation, möglicherweise infolge einer intravitrealer Bevacizumab-Injektion. Dem Patienten wurden 100 mg Ultralan täglich p.o. für 3 Tage und danach ausschleichend in 3 Tagesschritten rezeptiert. Im weiteren Verlauf zeigte sich keine Befundverschlechterung.

Abstract

A 74-year-old man presented with persistent metamorphopsias of the right eye 2 weeks after intravitreal injection of bevacizumab to treat choroidal neovascularization due to exudative age-related macular degeneration. The diagnosis reached was retinochoroiditis as an occult manifestation of sarcoidosis, possibly resulting from an intravitreal injection of bevacizumab. The patient received a prescription for 100 mg Ultralan to be taken daily for 3 days and then tapered in 3 day steps. During the further course no deterioration of the condition was observed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6
Abb. 7
Abb. 8

Literatur

  1. Avery RL, Pieramici DJ, Rabena MD et al. (2006) Intravitreal bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmology 113: 363–372

    Article  PubMed  Google Scholar 

  2. Bakri SJ, Snyder MR, Reid JM et al. (2007) Pharmacokinetics of intravitreal bevacizumab (avastin). Ophthalmology 114: 855–859

    Article  PubMed  Google Scholar 

  3. Chan CK, Meyer CH, Gross JG et al. (2007) Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 27(5): 541–551

    Article  PubMed  Google Scholar 

  4. Emerson MV, Lauer AK, Flaxel CJ et al. (2007) Intravitreal bevacizumab (avastin) treatment of neovascular age-related macular degeneration. Retina 27(4): 439–444

    Article  PubMed  Google Scholar 

  5. Fung AE, Rosenfeld PJ et al. (2007) The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90: 1344–1349

    Article  Google Scholar 

  6. Göbel W (2008) White-Dot-Syndrome. Ophthalmologe 105(1): 91–109

    Article  PubMed  Google Scholar 

  7. Heiduschka P, Fietz H, Hofmeister S et al. (2007) Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 48(6): 2814–2823

    Article  PubMed  Google Scholar 

  8. Joseph DP, Daniel P, Brantley MA, Grand MG. RAND (2003) Serpiginouslike choroiditis in a patient with cardiac sarcoidosis. Retina 23(1): 116

    Article  PubMed  Google Scholar 

  9. Kiss C, Michels S et al. (2006) Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina 26(8): 877–881

    Article  PubMed  Google Scholar 

  10. Kook D, Wolf A, Neubauer AS et al. (2007) Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD: Frequency and progress. Ophthalmologe [Epub ahead of print]

  11. Ladewig MS, Ziemssen F, Jaissle G et al. (2006) Intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmologe 103(6): 463–470

    Article  PubMed  CAS  Google Scholar 

  12. Manzano RP, Peyman GA, Khan P et al. (2006) Testing intravitreal toxicity of bevacizumab (avastin) Retina 26: 257–261

    Google Scholar 

  13. Maturi RK, Bleau LA, Wilson DL (2006) Electrophysiological findings after intravitreal bevacizumab (avastin) treatment. Retina 26: 270–274

    Article  PubMed  Google Scholar 

  14. Mennel S, Callizo J, Schmidt JC, Meyer CH (2007)Acute retinal pigment epithelial tear in the untreated fellow eye following repeated bevacizumab (avastin) injections. Acta Ophthalmol Scand 85: 689–690 49

    Article  PubMed  Google Scholar 

  15. Meyer CH, Ziemssen F, Heimann H (2008) Intravitreale Injektion. Ophthalmologe 105(2): 143–157

    Article  PubMed  CAS  Google Scholar 

  16. Monnet D, Levinson RD, Holland GN et al. (2007) Longitudinal cohort study of patients with birdshot chorioretinopathy. III. Macular imaging at baseline. Am J Ophthalmol 144(6): 818–828

    Article  PubMed  Google Scholar 

  17. Ralph D, Levinson MD et al. (2006) Research criteria for the diagnosis of birdshot chorioretinopahty: Results of an international consensus conference. Am J Ophthalmol 141(1): 185–187

    Article  Google Scholar 

  18. Ryan SJ, Maumenee AE (1980) Birdshot retinochoroidopathy. Am J Ophthalmol 89(1): 31–45

    PubMed  CAS  Google Scholar 

  19. Shahar J, Avery RL, Heilweil G et al. (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (avastin). Retina 26: 262–269

    Article  PubMed  Google Scholar 

  20. Spalton DJ, Hitchings RA, Hunter PA (2006) Atlas der Klinischen Ophthalmologie 304–308

  21. Weinberger AW, Thiel M, Mohammadi B et al. (2007) Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment. Am J Ophthalmol 144(2): 294–296

    Article  PubMed  CAS  Google Scholar 

  22. Ziemssen F, Bartz-Schmidt KU et al. (2006) (Neben-) Wirkungen der VEGF-Inhibition. Ophthalmologe 103(6): 484–491

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Augenklinik der Technischen Universität München, Ismaningerstraße 22, 81675, München, Deutschland

    M. Maier, N. Feucht, I. Lanzl, P. Kook & C.P. Lohmann

Authors
  1. M. Maier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Feucht
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Lanzl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Kook
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C.P. Lohmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Maier.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maier, M., Feucht, N., Lanzl, I. et al. Retinochoroidopathie nach intravitrealer Anti-VEGF-Behandlung. Ophthalmologe 106, 729–734 (2009). https://doi.org/10.1007/s00347-008-1839-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-008-1839-3

Schlüsselwörter

Keywords

Search

Navigation